dimanche 15 novembre 2026
RechercherExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· January 16, 2026

Aduro Clean Technologies gibt Ergebnisse für das zweite Quartal des Geschäftsjahres 2026 bekannt und informiert über den aktuellen Stand des Geschäfts

View original at globenewswire.com
Aduro Clean Technologies gibt Ergebnisse für das zweite Quartal des Geschäftsjahres 2026 bekannt und informiert über den aktuellen Stand des Geschäfts LONDON, Ontario, Jan…
Opening lines of the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Proceeds from the offering will be used primarily for advancing demonstration plant program, further R&D investments, and general corporate purposes

    80% confidence
  • In Q2 FY2026, Aduro achieved several important operational and strategic milestones while continuing to pursue scaling plan

    80% confidence
  • The $20M US public offering significantly strengthened the company's capital position and provided additional financial flexibility to support planned activities

    80% confidence
  • Aduro advanced commissioning of NGP pilot plant and made significant progress on demonstration plant program including global site selection

    80% confidence
  • Final site selection for demonstration plant is currently expected by end of January 2026

    80% confidence
  • Steam cracking trials showed stable furnace operation and achieved ethylene and propylene yields comparable to conventional fossil steam cracker feedstocks

    80% confidence

Data points we hold from this source

Aduro Clean Technologies Inc. · book value property plant equipment7729984 CAD
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Sources réconciliées : aucun conflit ouvert pour l'instant.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,959
faits reliés à leur source, et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,959 faits vérifiés avec la source5,585 documents sources archivés
Interrogez ces données → isubstrate.com
Aduro Clean Technologies gibt Ergebnisse für das zweite Quartal des Geschäftsjahres 2026 bekannt und informiert über den aktuellen Stand des Geschäfts: Source | Via News | fr.via.news